Advertisement

Search Results

Advertisement



Your search for Alice Goodman matches 1797 pages

Showing 101 - 150


bladder cancer
genomics/genetics

THOR Trial: Erdafitinib Improves Outcomes vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma

Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly improved overall survival, progression-free survival, and objective response rates compared with investigator’s choice of chemotherapy in patients with advanced urothelial cancers and FGFR2/3...

breast cancer
immunotherapy

Current Management of and Future Possibilities for Triple-Negative Breast Cancer

“Triple-negative breast cancer remains the most challenging subtype to treat because of its aggressive phenotype and limited treatment options,” stated Erica Michelle Stringer-Reasor, MD, who spoke at an education session on current approaches to treatment and future directions during the 2023 ASCO ...

Expert Point of View: David A. Braun, MD, PhD

David A. Braun, MD, PhD, of Yale Cancer Center, was the formal discussant of the abstract on the 4-year follow-up of the CLEAR trial. “We have made remarkable progress [in advanced renal cell carcinoma] and are now in the combination era of immunotherapy-based therapy and immunotherapy-based...

kidney cancer

CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer

At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...

Expert Point of View: Ann S. LaCasce, MD, MMSc

Formal discussant of the SWOG S1826 abstract, Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, Boston, said she was “excited” by these results. “The data speak for themselves. Nivolumab plus AVD [doxorubicin, vinblastine, dacarbazine] should be the treatment of choice, with more...

lymphoma

SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma

The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...

Expert Point of View: Mark Awad, MD, PhD

Formal discussant of KEYNOTE-671, Mark Awad, MD, PhD, of the Dana-Farber Cancer Institute, Boston, was optimistic about these data. “A hazard ratio of 0.58 for event-free survival and signals favoring overall survival in stage II to III non–small cell lung cancer [NSCLC] are truly impressive....

lung cancer

KEYNOTE-671 Trial: Perioperative Pembrolizumab Plus Chemotherapy Improves Outcomes in Stage II and III NSCLC

Neoadjuvant therapy with pembrolizumab plus platinum-based chemotherapy followed by surgery and then adjuvant pembrolizumab led to significantly improved event-free survival in patients with resectable stage II and III non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy...

Expert Point of View: Benjamin J. Solomon, MBBS, PhD

“Outcomes for patients with early-stage non–small cell lung cancer [NSCLC] remain poor despite potentially curative surgery and adjuvant cisplatin-based chemotherapy,” said formal abstract discussant Benjamin J. Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre and the University of Melbourne....

lung cancer

Adjuvant Osimertinib Improves Overall Survival in Resectable EGFR-Mutated NSCLC

The phase III ADAURA trial previously found that adjuvant use of osimertinib improved disease-free survival for completely resected EGFR-mutated non–small cell lung cancer (NSCLC) in patients with stage IB, II, or IIIA disease.1 The final analysis of ADAURA, which was presented at the 2023 ASCO...

skin cancer
immunotherapy

Expert Point of View: Zeynep Eroglu, MD

The formal discussant of the phase II SWOG S1512 trial was Zeynep Eroglu, MD, of the Department of Cutaneous Oncology at the Moffitt Cancer Center in Tampa, Florida. She congratulated Dr. Kendra and her coauthors for conducting a study in such a rare tumor. “I think we can say desmoplastic melanoma ...

skin cancer
immunotherapy

SWOG S1512 Trial: Pembrolizumab Achieves High Response Rates in Rare Type of Melanoma

The immune checkpoint inhibitor pembrolizumab achieved high response rates in patients with unresectable metastatic desmoplastic melanoma, a rare invasive tumor type, according to the results of the phase II SWOG S1512 trial presented at the 2023 American Association for Cancer Research (AACR)...

colorectal cancer
genomics/genetics

Expert Point of View: Lisa Newman, MD, MPH, FACS, FASCO

Commenting on this study on clinical genomic profiling for colorectal cancer, Lisa Newman, MD, MPH, FACS, FASCO, Chief of the Section of Breast Surgery and leader of the Multidisciplinary Breast Oncology Programs at Weill Cornell Medicine and NewYork-Presbyterian, commended the authors for...

colorectal cancer
genomics/genetics

Retrospective Study Finds Black Patients With Colorectal Cancer Had Fewer Actionable Genomic Mutations Than White Patients

Black individuals have a higher incidence of colorectal cancer than White individuals, and their outcomes are worse. Undoubtedly, reasons for this are multifaceted, but the disparity in outcomes may be partly explained by genomic differences, documented in a large retrospective study presented at...

solid tumors

In Case You Missed It: Brief Highlights From Studies Presented During AACR 2023

Presented here are some highlights of preliminary studies presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. These presentations provide signals for the utility of an off-the-shelf chimeric antigen receptor (CAR) T-cell product in renal cell carcinoma, an...

Expert Point of View: Christina Fotopoulou, MD, PhD

Christina Fotopoulou, MD, PhD, of Imperial College London, called DUO-O “a big, celebrated study” that breaks new ground, at least for a subset of patients. “We are beginning to see some encouraging data for immunotherapy in ovarian cancer,” she said as the invited discussant of the study. A chief ...

Expert Point of View: Jose Alejandro Rauh-Hain, MD, MPH

“This is an impressive presentation,” said formal discussant Jose Alejandro Rauh-Hain, MD, MPH, of The University of Texas MD Anderson Cancer Center, Houston. “Radical hysterectomy has intraoperative and postoperative complications that include gastrointestinal and genitourinary long-term...

gynecologic cancers

De-escalation of Surgery Feasible for Selected Patients With Low-Risk, Early-Stage Cervical Cancer

Many patients with early-stage, low-risk cervical cancer may be spared the side effects associated with radical hysterectomy and undergo simple hysterectomy with pelvic lymph node dissection instead, according to results of the international phase III SHAPE study presented at the 2023 ASCO Annual...

Expert Point of View: Roisin E. O’Cearbhaill, MD

Formal discussant of this late-breaking presentation, Roisin E. O’Cearbhaill, MD, of Memorial Sloan Kettering Cancer Center, New York, commented: “MIRASOL is confirmatory of SORAYA, the trial that led to FDA accelerated approval. The impressive data of MIRASOL show an overall survival advantage in ...

gynecologic cancers

MIRASOL Trial: First Targeted Therapy for Platinum-Resistant Ovarian Cancer to Improve Survival Outcomes

Mirvetuximab soravtansine-gynx, a novel antibody-drug conjugate, significantly improved progression-free and overall survival in patients with platinum-resistant, recurrent ovarian cancers that express high levels of folate receptor–alpha (FR-alpha), according to the results of the phase III...

Expert Point of View: Rita Nanda, MD

“I expect the NATALEE trial results will change clinical practice,” stated ASCO expert Rita Nanda, MD, Director of the Breast Oncology Program at University of Chicago Medicine. “Three different CDK4/6 inhibitors have all been shown to improve progression-free survival in the first- and second-line ...

breast cancer

Adjuvant Treatment With Ribociclib Reduces Risk of Recurrence in Hormone Receptor–Positive, HER2-Negative, Early-Stage Breast Cancer

The addition of the CDK4/6 inhibitor ribociclib to endocrine therapy significantly improved invasive disease–free survival in women with hormone receptor–positive, HER2-negative, early-stage breast cancer. These results of the phase III NATALEE trial were reported by lead author Dennis J. Slamon,...

Expert Point of View: Rimas Vincas Lukas, MD

Rimas Vincas Lukas, MD, of Northwestern University, was the formal discussant of this plenary session abstract on the INDIGO trial findings. “Because of its slowly progressive nature, glioma is insidious. The impact of the disease and its treatments has important consequences for patients,...

head and neck cancer

INDIGO Trial: IDH Inhibitor Improves Progression-Free Survival in Grade 2 IDH1/2-Mutated Gliomas

The oral IDH1/2 inhibitor vorasidenib significantly improved progression-free survival in patients with grade 2 gliomas expressing IDH1/2 mutations in the phase III INDIGO trial. These results, which were reported by lead author Ingo K. Mellinghoff, MD, FACP, of Memorial Sloan Kettering Cancer...

Expert Point of View: Devraj Basu, MD, PhD, FACS

Devraj Basu, MD, PhD, FACS, of the Perelman School of Medicine, University of Pennsylvania, an expert in human papillomavirus (HPV)-related oropharyngeal cancer, commented on this study: “This abstract shows lack of awareness of multiple types of HPV-associated cancer and a reduced awareness of...

solid tumors

Better Awareness of HPV-Associated Cancers Is Still Needed in the United States, Study Finds

Awareness of the link between the human papillomavirus (HPV) and HPV-associated cervical cancers has declined over time, and awareness of other HPV-associated cancers, such as oral, penile, and anal, remains low, according to a cross-sectional study of the U.S. population presented at the 2023...

gynecologic cancers

Pembrolizumab Added to Chemotherapy Improves Survival in Advanced Cervical Cancer Regardless of PD-L1 Expression

The addition of pembrolizumab to chemotherapy with or without bevacizumab led to improved overall survival and progression-free survival in women with persistent, recurrent, or metastatic cervical cancer in the final protocol-specified overall survival analysis of the KEYNOTE-826 trial presented at ...

genomics/genetics

Genetic Sequencing May Identify Cancers Often Missed by Traditional Screening Guidelines

Whole-exome sequencing of a large database identified carriers of mutations associated with hereditary cancer syndromes (ie, hereditary breast and ovarian cancers and Lynch syndrome). What was surprising was that among those carriers, about 40% did not satisfy the existing National Comprehensive...

Expert Point of View: Stephen Lam Chan, MD

Invited discussant of the IMbrave050 trial, Stephen Lam Chan, MD, of Chinese University of Hong Kong, put the study into context. “After curative treatment, recurrence remains a big problem [in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or...

hepatobiliary cancer

IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma

Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...

Expert Point of View: Kenneth C. Anderson, MD

Kenneth C. Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute, and Kraft Family Professor of Medicine, Harvard Medical School, was upbeat about the REGN5459 study and the field of melanoma studies in...

multiple myeloma

Novel Bispecific Antibody for Multiple Myeloma Shows High Response Rates in Early Trial

The bispecific antibody REGN5459 achieved a 90.5% overall response rate when given at the two highest doses in patients with relapsed or refractory multiple myeloma, according to the results of a phase I/II clinical trial.1 Although preliminary, the results of this first-in-human trial for the...

Expert Point of View: Margaret K. Callahan, MD, PhD

Formal discussant of the mRNA-4157-P201/KEYNOTE-942 trial, Margaret K. Callahan, MD, PhD, Research Director, Immunotherapeutics Program, Memorial Sloan Kettering Cancer Center, New York, agreed that finding an effective cancer vaccine has been challenging, and she is “cautiously optimistic” about...

skin cancer

Study Shows mRNA-Based Personalized Vaccine Plus Pembrolizumab Active in Melanoma for the First Time

The search for an effective cancer vaccine has been frustrating, but finally there may be light at the end of the tunnel. Adjuvant use of an investigational personalized mRNA vaccine (mRNA-4157) plus the PD-1 inhibitor pembrolizumab improved recurrence-free survival vs pembrolizumab alone in...

Expert Point of View: Roy S. Herbst, MD, PhD

Invited discussant Roy S. Herbst, MD, PhD, Deputy Director of the Yale Cancer Center, New Haven, Connecticut, called this “a very exciting abstract exploring when surgery meets immunotherapy.” He commented: “NSCLC is a big disease, affecting 2 million or more people worldwide, and this is the tip...

lung cancer

AEGEAN Trial Shows Benefit With Immunotherapy-Based Combination for NSCLC

Patients with treatment-naive resectable non–small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response rates compared with those who received neoadjuvant chemotherapy...

Expert Point of View: Rachna T. Shroff, MD

Formal discussant of this trial at the American Association for Cancer Research Annual Meeting, Rachna T. Shroff, MD, Associate Professor, Interim Chief of Hematology/Oncology, and Associate Director of Clinical Investigations, University of Arizona Cancer Center, said: “This is a very important...

hepatobiliary cancer

Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers

The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 trial presented at the 2023 American Association for Cancer...

solid tumors

Highlights of Novel Therapies Under Study in Genitourinary Cancers

Here are some brief reports from the 2023 ASCO Genitourinary (GU) Cancers Symposium that we hope are of interest. They include real-world evidence about the use of avelumab maintenance in metastatic urothelial carcinoma, data on the feasibility of sequencing radium-223 and Lu-177–PSMA-617 in...

Expert Point of View: Oliver Sartor, MD

The results of recent trials of PARP (poly [ADP-ribose] polymerase) inhibitor plus second-generation androgen receptor inhibitor combinations have had varying results in metastatic castration-resistant prostate cancer. Some trials suggest the benefit is confined to those with BRCA mutations and/or...

prostate cancer

PROpel Trial: Improvement in Progression-Free Survival With First-Line Olaparib Plus Abiraterone in Metastatic Prostate Cancer

The addition of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib to standard-of-care abiraterone in the first-line setting of metastatic castration-resistant prostate cancer achieved longer progression-free survival vs abiraterone alone, as demonstrated in the final results of the phase...

Expert Point of View: Mikkael Sekeres, MD, MS

Commenting on these studies of menin inhibitors, Mikkael Sekeres, MD, MS, Professor of Medicine and Chief of the Division of Hematology at the Sylvester Cancer Center, University of Miami Miller School of Medicine, was enthusiastic about the promise of these agents because they are targeted to...

leukemia

Menin Inhibitors Under Study in KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia

Menin inhibitors are making inroads in the treatment of acute myeloid leukemia (AML). These drugs selectively target KMT2A-rearranged or NPM1-mutant AML, and early studies suggest they will be a welcome addition for patients with these aberrations. KMT2A rearrangements occur in about 5% of patients ...

bladder cancer
immunotherapy

Expert Point of View: Xin Gao, MD

Xin Gao, MD, Assistant Professor, Harvard Medical School, Genitourinary Cancers Program, Mass General Cancer Center, commented on the results from TROPHY-U-01 cohort 2. “These data add to the overall data on the efficacy of sacituzumab govitecan in patients with metastatic urothelial cancer. This...

bladder cancer
immunotherapy

Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer

Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...

prostate cancer

Expert Point of View: Tyler Seibert, MD, PhD

Formal discussant of the FORMULA-509 trial, Tyler Seibert, MD, PhD, of the University of California San Diego, commented: “The important take-away of these results is who benefited from the intensification arm. The overall cohort with a PSA [prostate-specific antigen] level up to 0.5 ng/mL did not, ...

prostate cancer

FORMULA-509: Intensified Postoperative Regimen May Be of Benefit in Subset of High-Risk Prostate Cancer

The addition of abiraterone acetate and apalutamide to standard of care gonadotropin-releasing hormone (GnRH) agonist for 6 months and radiation therapy failed to improve progression-free survival and metastasis-free survival after prostatectomy compared to bicalutamide plus a GnRH agonist and...

prostate cancer

Expert Point of View: Elena Castro, MD, PhD

The formal discussant of the TALAPRO-2 trial, Elena Castro, MD, PhD, took issue with the conclusion of Dr. Neeraj Agarwal and colleagues that these results support the use of talazoparib plus enzalutamide as a first-line treatment of patients with metastatic castration-resistant prostate cancer,...

prostate cancer

TALAPRO-2: Talazoparib Plus Enzalutamide Extends Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer

The addition of the poly (ADP ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide achieved a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...

Expert Point of View: Monica Chatwal, MD

Medical oncologist Monica Chatwal, MD, of Moffitt Cancer Center, Tampa, Florida, commented on the take-home points from the ARASENS trial. “The ARASENS trial continues to show a survival benefit for a triplet therapy approach in metastatic hormone-sensitive prostate cancer with androgen-deprivation ...

Advertisement

Advertisement




Advertisement